| Period | Period Low | Period High | Performance | |
|---|---|---|---|---|
| 1-Month | 9,399.000 +13.88% on 06/14/22 | | 11,054.002 -3.17% on 06/29/22 | +262.000 (+2.51%) since 06/01/22 |
| 3-Month | 9,399.000 +13.88% on 06/14/22 | | 11,054.002 -3.17% on 06/29/22 | +628.000 (+6.23%) since 04/01/22 |
| 52-Week | 8,029.000 +33.32% on 09/17/21 | | 11,054.002 -3.17% on 06/29/22 | +1,962.000 (+22.44%) since 07/01/21 |
AstraZeneca's EVUSHELD (tixagevimab co-packaged with cilgavimab), a long-acting antibody (LAAB) combination, has received emergency use authorization (EUA) in the US for the pre-exposure prophylaxis...
MARSEILLE, France, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN)...
Angeles Equity Partners, LLC (“Angeles”), a private investment firm focused on value creation through operational transformation, today announced the appointment of Debbie White to the Board of Directors...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM; HKEX: 13) announces the first commercial sale in...
– HUTCHMED will review these highlights as part of its company update audio call and webcast on Wednesday, May 26 at 9 a.m. EDT to discuss data disclosures, its PD-1/L1 combination study strategy and...
NEW YORK, April 27, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company,...
SAN FRANCISCO, March 01, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN) and its partner, AstraZeneca (LSE/STO/Nasdaq: AZN), today announced that the Cardiovascular and Renal Drugs Advisory Committee...
Multi-year, pan-portfolio deal extends Adaptive’s proprietary immunoSEQ T-MAP offering, originally launched for COVID-19, into oncology
AstraZeneca and Alexion Pharmaceuticals, Inc. (Alexion) have entered into a definitive agreement for AstraZeneca to acquire Alexion.
New data show safety and efficacy of roxadustat in treating anemia secondary to lower-risk myelodysplastic syndrome s (MDS) regardless of ring sideroblast (RS) or baseline e rythro...
| 3rd Resistance Point | 11,205.997 |
| 2nd Resistance Point | 11,075.997 |
| 1st Resistance Point | 10,937.999 |
| Last Price | 10,680.000 |
| 1st Support Level | 10,670.001 |
| 2nd Support Level | 10,540.001 |
| 3rd Support Level | 10,402.003 |
| 52-Week High | 11,054.002 |
| Last Price | 10,680.000 |
| Fibonacci 61.8% | 9,898.451 |
| Fibonacci 50% | 9,541.501 |
| Fibonacci 38.2% | 9,184.551 |
| 52-Week Low | 8,029.000 |
